Morgan Stanley Initiates Coverage On Integra Lifesciences with Equal-Weight Rating, Announces Price Target of $59
Morgan Stanley analyst Drew Ranieri initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Equal-Weight rating and announces Price Target of $59.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 326 stocks hit new 52-week lows.
Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $67
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $70 to $67.
Integra LifeSciences Posts Street Beating Earnings, Backs FY22 Guidance
Integra LifeSciences Holdings Corp (NASDAQ:IART) reported Q1 FY22 sales of $376.6 million, +4.6% Y/Y on a reported basis and 5.6%…
Integra Lifesciences Q1 Adj. EPS $0.74 Beats $0.68 Estimate, Sales $376.60M Beat $362.04M Estimate
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.68 by 8.82 percent. This is a 7.25 percent increase over earnings of $0.69 per share from
Earnings Scheduled For April 27, 2022
Companies Reporting Before The Bell
• Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering rate hike fears.